Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)
NCT ID: NCT02163720
Last Updated: 2020-09-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
101 participants
OBSERVATIONAL
2014-07-10
2018-09-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer
NCT00113607
Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse
NCT00189553
A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625)
NCT00780039
Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum
NCT05512676
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT01846611
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Yondelis®-Caelyx®-relapse ovarian cancer
Yondelis®-Caelyx®-relapse ovarian cancer
Yondelis®-Caelyx®
Observation of Yondelis®-Caelyx® administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Yondelis®-Caelyx®
Observation of Yondelis®-Caelyx® administration
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with an epithelial ovarian cancer, fallopian tube or peritoneal who will receive Yondelis®-Caelyx® in relapse platinum-sensitive
* Patients should be informed of the study orally and should not have any objection their data to be processed
Exclusion Criteria
* Patient non-affiliated to a social security scheme.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
PharmaMar
INDUSTRY
ARCAGY/ GINECO GROUP
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Frédéric SELLE, MD
Role: PRINCIPAL_INVESTIGATOR
Hôpital Tenon
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre de Radiothérapie et d'Oncologie
Agen, , France
Clinique de l'Europe
Amiens, , France
ICO Paul Papin
Angers, , France
Hôpital de la Côte Basque
Bayonne, , France
Hôpital jean Minjoz
Besançon, , France
Clinique Tivoli
Bordeaux, , France
Hôpital Fleyriat
Bourg-en-Bresse, , France
Hôpital Morvan - Centre Hospitalier Universitaire
Brest, , France
Cabinet d'Oncologie - Hôpital Privé Sainte Marie
Chalon-sur-Saône, , France
Centre Hospitalier de Cholet
Cholet, , France
Hôpital Privé Drôme Ardèche - Clinique Pasteur
Guilherand-Granges, , France
Hôpital Louis Pasteur
Le Coudray, , France
Centre Oscar Lambret
Lille, , France
Centre Hospitalier Universitaire Dupuytren
Limoges, , France
CHU Dupuytren
Limoges, , France
Centre Léon Bérard
Lyon, , France
institut Paoli Calmette
Marseille, , France
Centre Azuréen de Cancérologie
Mougins, , France
Centre d'oncologie de Gentilly
Nancy, , France
Centre Hospitalier Régional
Orléans, , France
Hôpital Tenon
Paris, , France
Hôpital de la Milétrie - Centre Hospitalier Universitaire de Poitiers - Pôle Régional de Cancérologie
Poitiers, , France
Clinique Courlancy
Reims, , France
Institut Jean Godinot
Reims, , France
Clinique Armoricaine de Radiologie
Saint-Brieuc, , France
Clinique de l'Alliance
Saint-Cyr-sur-Loire, , France
ICO Centre René Gauducheau
Saint-Herblain, , France
Clinique de l'Union
Saint-Jean, , France
GHPSO - Site Senlis
Senlis, , France
Centre de Radiothérapie - Clinique Sainte-Anne
Strasbourg, , France
Clinique Saint Jean
Toulon, , France
Institut Claudius Regaud
Toulouse, , France
Institut de Cancérologie Gustave Roussy
Villejuif, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Selle F, Heudel PE, Hardy-Bessard AC, Pozet A, Meunier J, Gladieff L, Lotz JP, Provansal M, Augereau P, Berton D, Bonichon-Lamichhane N, Orfeuvre H, Pautier P, Kalbacher E, Tazi Y, Spaeth D. GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer. Anticancer Res. 2020 Jul;40(7):3939-3945. doi: 10.21873/anticanres.14385.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PROSPECTYON (GINECO-OV229)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.